TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05100641: Randomized Phase 3 Trial of Standard Care Plus AV-GBM-1 vs Autologous Monocytes as Adjunctive Therapy Following Primary Surgery Plus Concurrent Radiation-temozolomide in Patients With Newly Diagnosed Glioblastoma

Sponsor: Aivita Biomedical, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 672 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT05100641 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05100641 Rescue Dossier →